This is a randomized, controlled trial to evalute the efficacy of treatment with DHPG (12mg/kg/day) Vs. no treatment in neonates with symptomatic congenital cytomegalovirus and CNS disease. Only babies with symptomatic congenital infection who stand to derive therapeutic benefit are eligible for the study.
NIH ExPorter
NIH ExPorter